| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
Carzenide targets carbonic anhydrase (CA), specifically the CAII isozyme. It is a competitive inhibitor. It displays high inhibitory activity against human CA2 (Ki = 33.0 nM) and human CA9 (Ki = 26.0 nM), while showing moderate inhibition against human CA1 (Ki = 109.0 nM).
|
|---|---|
| ln Vitro |
In vitro, Carzenide inhibits carbonic anhydrase activity. At 100 µM for 2 hours of pretreatment in HeLa cells, it makes FMRs-CA-evoked fluorescent signals negligible. Its inhibitory activity against various CA isozymes has been characterized, with Ki values of 33.0 nM for CA2, 26.0 nM for CA9, and 109.0 nM for CA1.
|
| ln Vivo |
In vivo activity of Carzenide has not been detailed in the provided search results. As the major circulating metabolite of Mafenide, it contributes to the overall pharmacological profile of the parent drug.
|
| Enzyme Assay |
In vitro enzyme assays measure the inhibition of carbonic anhydrase activity. The compound is incubated with the enzyme and a substrate, and the enzymatic activity is measured to determine the inhibition constant (Ki).
|
| Cell Assay |
In vitro cell-based assays, such as those using HeLa cells, can be used to study the compound's effects on cellular processes. Cells are treated with Carzenide, and specific readouts, such as fluorescence signals from CA-sensitive probes, are measured.
|
| Animal Protocol |
In vivo animal studies have not been detailed in the provided search results. As a metabolite and a research compound, it may be studied in animal models of epilepsy or cancer.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Carzenide are related to its role as the major circulating metabolite of Mafenide. Its formation and elimination contribute to the PK profile of the parent drug.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Carzenide has not been detailed in the provided search results. It is an intermediate for organic synthesis and is used for research purposes.
|
| Additional Infomation |
Carzenide is a sulfonamide drug.
Carzenide is also known as 4-Sulfamoylbenzoic acid and p-carboxybenzenesulfonamide. It is supplied as a white to off-white solid powder with a purity of ≥98%. |
| Molecular Formula |
C7H7NO4S
|
|---|---|
| Molecular Weight |
201.19978
|
| Exact Mass |
201.009
|
| CAS # |
138-41-0
|
| PubChem CID |
8739
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
449.0±47.0 °C at 760 mmHg
|
| Melting Point |
285-295 °C(lit.)
|
| Flash Point |
225.4±29.3 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
0.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
284
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)C1=CC=C(S(=O)(N)=O)C=C1
|
| InChi Key |
UCAGLBKTLXCODC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)
|
| Chemical Name |
4-sulfamoylbenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~497.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9702 mL | 24.8509 mL | 49.7018 mL | |
| 5 mM | 0.9940 mL | 4.9702 mL | 9.9404 mL | |
| 10 mM | 0.4970 mL | 2.4851 mL | 4.9702 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
